Nami Therapeutics Corporation
56 Farmstead Rd
Storrs, Connecticut 06268
Website: https://www.namitherapeutics.com
Email: info@namitherapeutics.com
General Information:
Nami Therapeutics is an innovative radiopharmaceutical company focused on developing tumor-specific precision therapeutics to treat cancer patients. The mission is to provide another chance at a cancer-free life for oncology patients. Nami Therapeutics is known for the cutting-edge research on nanocarriers designed for precise and targeted delivery of therapeutics. Founded in 2018 based on the pioneering research of Dr. Xiuling Lu (University of Connecticut) and Dr. Michael Jay (University of North Carolina), Nami has developed specifically designed nanocarriers, XLNT-1, for targeted delivery of radiotherapies to peritoneal metastatic tumors. The Primary indication addresses a significant unmet need: treating ovarian cancer metastasis. Preclinical studies have demonstrated tumor-specific delivery of radiation, improved survival rates, and a favorable safety profile. The initial radiotherapeutic nanoparticle product, XLNT-1, is targeting first-in-human studies in 2025.
The platform technology has the potential for multiple applications, including pancreatic, gastrointestinal, and prostate cancers, following initial proof of concept in treating ovarian cancer.